Several monoclonal antibodies (mAbs) targeting distinct type 2 inflammatory players (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab targeting IgE, IL-5, IL-5 receptor, IL-4 receptor, and TSLP, respectively), initially available for the treatment of severe asthma only, were found to significantly reduce CRSwNP inflammation and symptoms when used to treat comorbid patients. The gene discussed is IL5; the disease is asthma.